<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02629341</url>
  </required_header>
  <id_info>
    <org_study_id>BONEFOODS</org_study_id>
    <nct_id>NCT02629341</nct_id>
  </id_info>
  <brief_title>Functional Yogurt Powder Effect on Bone Health Biomarkers</brief_title>
  <acronym>bonefoods</acronym>
  <official_title>Functional Yogurt Powder Effect on Bone Health Biomarkers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Investigación Hospital Universitario La Paz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto de Investigación Hospital Universitario La Paz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate the therapeutic effect of a functional yogurt&#xD;
      powder on menopausal, middle-aged women at high risk of osteoporosis. The functional yogurt&#xD;
      powder containing Calcium, D, K, C vitamins, Zn, Mg, L-leucin and the Lactobacillus plantarum&#xD;
      3547 probiotic, was developed to benefit bone health and in the long term may contribute to&#xD;
      the prevention of osteoporosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, parallel, double-blind, placebo controlled clinical trial to evaluate the effect&#xD;
      of a functional yogurt powder on bone health biomarkers in menopause, middle-aged women at&#xD;
      high risk of osteoporosis.&#xD;
&#xD;
      78 volunteers will be recruited at the La Paz University Hospital of Madrid. Participants&#xD;
      should meet the next inclusion criteria: being menopausal, aged between 50 and 65 years,&#xD;
      IMC≥18.5 &lt;35 Kg/m2 and having a diagnosis of osteopenia without pharmacological treatment&#xD;
      (Volunteers without osteopenia diagnosis should meet two of the next: dairy intake under 2&#xD;
      servings a day, sedentary lifestyle and/or smokers of more than 5 cigarettes a day).&#xD;
&#xD;
      Participants will be randomized in two arms:&#xD;
&#xD;
        1. Functional yogurt powder arm: they will receive over 24 weeks a daily serving of the&#xD;
           functional yogurt powder containing Calcium, D, K, C vitamins, Zn, Mg, L-leucin and the&#xD;
           Lactobacillus plantarum 3547 probiotic.&#xD;
&#xD;
        2. Control yogurt powder arm: they will receive over 24 weeks a daily serving of the&#xD;
           control yogurt powder (not enriched).&#xD;
&#xD;
      All participants will be advised to follow a healthy diet and practice physical activity.&#xD;
&#xD;
      Follow up will include 3 individualized visits and 4 group visits to check the product intake&#xD;
      compliance and the tolerance to the product. The primary outcome, vitamin D level, will be&#xD;
      measured at the beginning (basal condition) and at the end of the intervention (24 weeks).&#xD;
      Other bone health biomarkers (Parathyroid hormone (PTH) calcium, phosphorus, calcitonin,&#xD;
      osteocalcin, adrenocorticotropic hormone (ACTH),osteopontin, osteoprotegerin, sclerostin,the&#xD;
      N-terminal telopeptide (NTx) and C-terminal telopeptide CTx) and safety issues (transaminases&#xD;
      and creatinine) will be measured at the same time points (0 and 24 weeks).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>changes in plasma 25(OH)D concentration</measure>
    <time_frame>0 and 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Body composition by Dual-energy X-ray absorptiometry (DXA)</measure>
    <time_frame>0 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline calcium levels in blood</measure>
    <time_frame>0 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Parathyroid hormone (PTH)</measure>
    <time_frame>0 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline adrenocorticotropic hormone (ACTH)</measure>
    <time_frame>0 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Calcitonin</measure>
    <time_frame>0 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline osteocalcin</measure>
    <time_frame>0 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Osteopontin</measure>
    <time_frame>0 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Osteoprotegerin</measure>
    <time_frame>0 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline sclerostin</measure>
    <time_frame>0 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline phosphorus</measure>
    <time_frame>0 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline N-terminal telopeptide</measure>
    <time_frame>0 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline the C-terminal telopeptide</measure>
    <time_frame>0 and 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>OSTEOPENIA</condition>
  <arm_group>
    <arm_group_label>Functional yogurt powder</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm will receive one daily serving of the functional yogurt which is enriched in Calcium, D, K, C vitamins, Zn, Mg, L-leucin and the Lactobacillus plantarum 3547 probiotic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control yogurt powder</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This arm will receive one daily serving of the control yogurt which consists of a regular yogurt not enriched</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Functional yogurt powder</intervention_name>
    <description>Once daily during 24 weeks, 150g of yogurt powder enriched with:&#xD;
Calcium (mg) 501 D3 Vitamin (Colecalciferol) (μg(UI)) 6(240) K Vitamin (μg) 80 C Vitamin (mg) 100 Zinc (mg) 10,39 Magnesium (mg) 250,5 L-Leucin (g) 1 Lactobacillus plantarum 3547 (ufc) 1x10e10</description>
    <arm_group_label>Functional yogurt powder</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Control yogurt powder</intervention_name>
    <description>Once daily during 24 weeks, 150g of yogurt powder not enriched, isocaloric and with an equal macronutrient composition than the functional yogurt</description>
    <arm_group_label>Control yogurt powder</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  With healthy weight, overweight or obesity type I (IMC ≥18.5 &lt;35 Kg/m2);&#xD;
&#xD;
          -  With diagnosis of osteopenia without pharmacological treatment or that meet at least&#xD;
             two of the following criteria:&#xD;
&#xD;
               -  Dairy intake under 2 servings daily in the last year&#xD;
&#xD;
               -  Sedentary lifestyle (measured with the International physical activity&#xD;
                  questionary IPAQ)&#xD;
&#xD;
               -  Smokers of more than 5 cigarettes daily&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe diseases (hepatic, kidney, cancer…)&#xD;
&#xD;
          -  Renal failure (defined as serum creatinine level &gt;200 mol/L)&#xD;
&#xD;
          -  Phosphate binding antacids (&gt; 6 months a year)&#xD;
&#xD;
          -  Oral glucocorticoids (&gt;5 mg/day of prednison equivalent in the last 8 months or a&#xD;
             total dose of 2g of prednison equivalent in the last 12 months)&#xD;
&#xD;
          -  Local treatment with injectable glucocorticoids (&gt;5 injections/year)&#xD;
&#xD;
          -  Treatment with inhaled glucocorticoids (&gt;6months in the last year and more than 2&#xD;
             mg/day of prednison equivalent)&#xD;
&#xD;
          -  Previous or concomitant treatment for metabolic bone disease&#xD;
&#xD;
          -  Use of hormone replacement therapy (oral estrogen, estradiol vaginal ring,&#xD;
             antiestrogen, progesterone)&#xD;
&#xD;
          -  Anabolic steroid use in the last 3 months or more than one in the last 6 months&#xD;
&#xD;
          -  Estradiol implants in the last 3 years&#xD;
&#xD;
          -  Isoflavan use in the last 6 months or more than once a month for the last 12 months&#xD;
&#xD;
          -  Calcitonin use in the last month or more than 1 month in the last 6 months&#xD;
&#xD;
          -  Concomitant use of nutritional supplements with silicon, horsetail extracts, bamboo,&#xD;
             colloidal silicic acid or silanol derivatives in the last 6 months&#xD;
&#xD;
          -  Hyperparathyroidism and/or hyperthyroidism&#xD;
&#xD;
          -  Chronic intestinal disease (Gastritis, ulcerative colitis, irritable bowel disease,&#xD;
             pseudomembranous colitis, inflammatory bowel disease, Crohn disease, etc)&#xD;
&#xD;
          -  Dementia, mental disease or diminished cognitive function&#xD;
&#xD;
          -  Mayor surgery in the last month or gastrointestinal surgery in the last 3 months&#xD;
&#xD;
          -  Prebiotic, probiotic ad/or symbiotic consumption, antioxidant supplements, supplements&#xD;
             with omega 3, vitamins or minerals in the last 2 weeks prior to the start of the study&#xD;
&#xD;
          -  Participation in programs and / or drug use for weight control in the last 6 months&#xD;
&#xD;
          -  Alcohol consumption over 30g/day&#xD;
&#xD;
          -  Habitual laxative use and non acceptance in giving up its use during the study&#xD;
&#xD;
               -  Individuals using topic glucocorticoids can enter the trial&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carmen Gomez Candela, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario La Paz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitairo La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>December 10, 2015</study_first_submitted>
  <study_first_submitted_qc>December 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2015</study_first_posted>
  <last_update_submitted>December 10, 2015</last_update_submitted>
  <last_update_submitted_qc>December 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>woman osteopenia osteoporosis enriched calcium vit D yogurt</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

